The FDA has granted Orphan Drug designation to TNP-2092 (TenNor Therapeutics) powder for intravenous IV injection for the treatment of prosthetic joint infections.
The prevalence of mental distress is 16.8 percent and the prevalence of depression is 32.1 percent among adults with arthritis.
Researchers have found that tofacitinib, a drug approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, might also treat leaky gut.
Interleukin (IL) therapy for the treatment of rheumatologic diseases may increase the risk for serious infections, opportunistic infections, and cancer.
The addition of a second and third fracture-associated drug (FAD) is associated with an increase in hip fracture risk.
The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab; AbbVie).
Obese and overweight older individuals who lose weight have lower bone mineral density (BMD) in their hips.
Contrary to expectations, the prevalence of cannabis use disorder (CUD) decreased significantly among individuals reporting daily/almost daily cannabis use between 2002 and 2016.
Elevated calcium levels may lead to suboptimal growth of bone, according to the study’s findings.
Researchers assessed the effectiveness and safety of direct-acting antiviral therapy for patients with concomitant hepatitis C virus infection and rheumatic diseases, including rheumatoid arthritis.
Individuals with type 2 diabetes (T2D) are at higher risk for sustaining an incident vertebral fracture (VF) compared with individuals without T2D.
Adalimumab exposure in pregnancy does not increase the risk for birth defects.
There is insufficient evidence to support the use of medical cannabis or cannabis-related medications for the treatment of musculoskeletal and autoimmune disorders.
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.